Last updated on September 2018

Efficacy and Safety of Switching From TDF to TAF in Adults With Chronic Hepatitis B Who Are Virologically Suppressed


Brief description of study

The primary objectives of this study are to evaluate the efficacy, safety, and tolerability of switching to tenofovir alafenamide (TAF) versus continuing tenofovir disoproxil fumarate (TDF) in virologically suppressed adults with chronic hepatitis B virus (HBV) infection.

Clinical Study Identifier: NCT02979613

Contact Investigators or Research Sites near you

Start Over

Gilead Study Team

Los Angeles, CA United States

Gilead Study Team

Palo Alto, CA United States

Gilead Study Team

Pasadena, CA United States

Gilead Study Team

San Diego, CA United States

Gilead Study Team

San Francisco, CA United States

Gilead Study Team

San Jose, CA United States

Gilead Study Team

Baltimore, MD United States

Gilead Study Team

Boston, MA United States

Gilead Study Team

Novi, MI United States

Gilead Study Team

Flushing, NY United States

Gilead Study Team

New York, NY United States

Gilead Study Team

Philadelphia, PA United States

Gilead Study Team

Nashville, TN United States

Gilead Study Team

Edmonton, Canada

Gilead Study Team

Toronto, Canada

Gilead Study Team

Vancouver, Canada

Gilead Study Team

Hong Kong, Hong Kong

Gilead Study Team

Kowloon, Hong Kong

Gilead Study Team

Goyang, Korea, Republic of

Gilead Study Team

Daegu, Korea, Republic of

Gilead Study Team

Goyang-si, Korea, Republic of

Gilead Study Team

Seoul, Korea, Republic of

Gilead Study Team

Barcelona, Spain

Gilead Study Team

Majadahonda, Spain

Gilead Study Team

Kaohsiung, Taiwan

Recruitment Status: Closed


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.